Costs, challenges and opportunities of decentralised chimeric antigen receptor T-cell production: a literature review and clinical experts’ interviews
Authors:
- 28 August 2024
- journal article
- research article
- Published by BMJ in European Journal of Hospital Pharmacy
- Vol. 32 (3) , 202-208
Abstract
The objectives were to summarise the evidence and clinical experts’ views comparing the use of decentralised produced chimeric antigen receptor (CAR) T-cell therapies versus commercially available products, regarding drug costs, time to finalised product and other reported advantages, disadvantages, challenges and facilitators. A literature review according to the PRISMA guidelines was conducted in Medline, Embase and Trip databases. Publications were included if they reported information on cost estimates, time to finalised products and other outcomes of interest of a decentralised CAR T-cell production strategy. A structured interview guide was developed and used for qualitative expert interviews. Five experts were purposively selected, and interviews were either conducted face-to-face or online, and recorded for the purpose of transcription. Transcripts were analysed and categories and codes extracted. Reporting is based on the COREQ checklist for reporting qualitative research. Costs of decentralised produced CAR T-cells appear to be lower by a factor two to 14, compared with commercial products. But there is high uncertainty about this estimate, because it is unclear whether cost components included are comparable and due to the heterogeneity of the studies. The most commonly reported advantages were proximity to patients and decreased product risks and costs, whereas the continuing dependency on centrally manufactured reagents and specific characteristics of ‘fresh’ CAR T-cells are reported as disadvantages. Compliance with regulatory requirements is mentioned as the biggest challenge. The availability of closed-system production devices is reported as one main facilitator, as are clear commitment, secured financing and knowledge transfer from already experienced centres. Apparent cost differences open a field for healthcare decision-makers to discuss and justify investment costs for implementation of a complementing decentralised production programme and to realise other associated benefits of such a strategy, such as flexibility, patient proximity and expanding patient access.Keywords
This publication has 24 references indexed in Scilit:
- Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in IndiaBone Marrow Transplantation, 2022
- Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphomaTransplantation and Cellular Therapy, 2022
- Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy TreatmentsCurrent Hematologic Malignancy Reports, 2021
- Comparison between centralized and decentralized supply chains of autologous chimeric antigen receptor T-cell therapies: a UK case study based on discrete event simulationCytotherapy, 2021
- Cost of decentralized CAR T‐cell production in an academic nonprofit settingInternational Journal of Cancer, 2020
- CART manufacturing process and reasons for academy-pharma collaborationImmunology Letters, 2020
- Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) ImmunotherapyCurrent Hematologic Malignancy Reports, 2019
- GMP CAR-T cell productionBest Practice & Research Clinical Haematology, 2018
- Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy – Moving Target for Industry?Pharmaceutical Research, 2018
- Towards a commercial process for the manufacture of genetically modified T cells for therapyCancer Gene Therapy, 2015